Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Diagnostic commercialisation company Diaceutics reinstated annual guidance on recovery in US pharmaceutical sales after swinging to an annual loss in 2020.
For the year-ended 31 December 2020, the pre-tax loss was £0.7 million compared with a profit of £0.5 million year-on-year as revenue fell 6% to £12.7 million.
Looking ahead, the company reinstated guidance as activity had returned close to pre-pandemic levels by year-end.
'Recent Market data indicates that US Pharma commercial activity had returned to 95% of pre-COVID-19 levels by the end of December 2020,' the company siad.
'On balance, given the positive and cautious approach to H1 2021, the board have approved the re-instatement of guidance for 2021,' the company said.
At 9:04am: (LON:DXRX) share price was 0p at 140p